WHO GMP for Pharmaceutical Excipients – Comprehensive Bullet Notes

Background & Rationale

• Excipients often used in large quantities; impurities can transfer unchanged into finished pharmaceutical products (FPPs).
• Historical incidents (e.g., diethylene glycol poisonings) led to patient deaths, underlining the need for stronger controls.
• Finished-product manufacturers are highly dependent on excipient suppliers; therefore, GMP principles must be applied throughout the excipient life-cycle.
• Concepts emphasised in the 2025 revision:
  • Life-cycle thinking & continual improvement.
  • Integrated Quality Management Systems (QMS).
  • Systematic Quality Risk Management (QRM).
  • Alignment with Good Storage, Trade & Distribution Practices (GDP/GTP).

Purpose & Scope (Section 1)

• Provide guidance on production, control, storage & distribution of pharmaceutical excipients.
• Excludes environmental protection & personnel-safety legislation.
• Recognises that excipients may have multiple industrial grades; pharmaceutical manufacturers must secure a suitable grade.
• Additional, tighter controls mandated for high-risk excipients (see Appendix 2).

Document Architecture (Section list, p.124)

• 18 core chapters (Quality management → Storage & distribution).
• 2 appendices:
  • Appendix 1 – Risk management methodology.
  • Appendix 2 – Examples of high-risk excipients/contaminants.

Glossary (selected critical terms)

• Acceptance criteria – numerical limits/ranges for test results.
• Adulterated – product unsafe, filthy or out of GMP compliance.
• Batch/Lot – homogeneous quantity; continuous production fraction OK.
• Critical – parameter that must meet predefined criteria.
• Excipient for pharmaceutical use – non-API aiding processing, stability, ID, bioavailability, etc.
• Rework vs. Reprocess – rework = alternate steps; reprocess = repeating established step.
• Shelf-life – period during which excipient complies with spec ⇒ determines retest/expiry date.
• Validation vs. Verification vs. Qualification – hierarchical assurance activities.

Quality Management System (QMS) (Section 3)

• Senior management owns quality; must allocate resources, set policy & objectives.
• QMS covers entire life-cycle: receipt → distribution.
• Written procedures, records, job descriptions & resource planning essential.
• Mandatory subsystems:
  • CAPA & change-control.
  • Supplier management & outsourced-activity oversight.
  • Batch release by an independent Quality Unit.
  • Product Quality Review (PQR).

Quality Risk Management (3.1)

• Follows WHO QRM guideline & ICH Q9.
• Must cover assessment → control → communication → review.
• Suggested high-level ranking parameters:
  • Functionality in formulation.
  • Route of administration.
  • Contamination potential.
  • Complexity of synthesis/supply chain.
  • Prior knowledge/history.
  • Packaging size.
• Supply-chain risk score: complexity, performance history, QMS certification, etc.
• Formal tools encouraged – HACCP, FMEA; Risk Priority Number formula $RPN=S\times O\times D$.

Management Review (3.2)

• Periodic, minutely documented; covers KPIs on audits, deviations, OOS, maintenance, CAPA, etc.

Pharmaceutical Quality System Processes

4 – Complaints

• Written SOP; record date, complainant, batch, investigation, response, disposition.
• Trend analysis required.

5 – Recalls

• Authorized recall SOP: roles, notification pathways, handling.
• Immediate authority notification if patient-harm risk.

6 – Returns

• Quarantine & documented decision tree (reuse/destroy).
• Certificate of destruction for disposals; cleaning & delabelling of reusable containers.

7 – Self-Inspection & Audits

• Programme with unbiased team; covers premises → validation.
• Particular focus when excipient destined for sterile dosage forms (pyrogen-free assurance).

8 – Personnel

• Adequate number & competency; written responsibilities.
• Regular GMP & job-specific training; documented assessment of understanding.

9 – Sanitation & Hygiene

• Risk-based controls for areas, equipment & personnel habits.
• Prohibit smoking, food, jewellery in production/QC zones.

10 – Documentation & Data Integrity

• Good Documentation Practices (GDP) & electronic‐record compliance.
• Retention time > product retest/expiry.
• Mandatory SOPs list (equipment, OOS, recalls, etc.).
• Batch manufacturing records must confirm: homogeneity, traceable samples, validated shelf-life, no adulteration.
• Electronic systems ⇒ audit trails, privileges, backup.

11 – Premises

• Layout minimises errors & cross-contamination; adequate lighting, HVAC.
• Dedicated facilities if health-based exposure limits (HBEL) dictate.

12 – Equipment & Utilities

• Designed/maintained to avoid mix-ups & contamination.
• Calibration, verification schedules; records retained.
• Computerised systems validated; comply with data integrity.
• Utilities (HVAC, water, N₂, compressed air) risk-assessed; water meets spec.

13 – Materials Management

• Approved-supplier programme; traceability for all raw & packaging materials.
• Scientific justification for use of recovered solvents.
• Non-conforming material SOP with Quality-Unit disposition.

14 – Production Operations

• Weigh/measure in controlled areas; labelled containers.
• In-process controls defined; sampling maintains integrity.
• Blending must ensure homogeneity; blending to hide OOS is prohibited.
• Rework allowed only after risk assessment & QA approval; full testing & stability evaluation required.
• Reprocessing acceptable if pre-evaluated & documented.

15 – Qualification & Validation

• Extent based on risk; evidence that premises, utilities & processes deliver expected outcome consistently.

16 – Quality Control (QC)

• QC labs suitably designed; equipment qualified.
• Specs aligned with pharmacopoeia; impurity-specific, stability-indicating methods.
• Certificate of Analysis (CoA) must quote tests, limits, dates, signatures.
• Stability programme details: number of batches, conditions (stress & normal), schedule ≥ annually; assign expiry/retest dates.

17 – Life-Cycle & Continuous Improvement

• Root-cause tools, trending of complaints/OOS/audit findings feed improvement loop.

18 – Storage & Distribution

• Clean, dry, ventilated areas; special conditions monitored & recorded.
• Pest-control programme.
• Distribution maintains identity, integrity & labelled conditions; traceability enabled for recall.

Appendix 1 – Risk Management Deep Dive

• SOP describing policy & tools mandatory.
• Multidisciplinary team; quantitative (preferred) or qualitative scoring.
• Broad risk catalogue: raw materials, solvents, equipment, environment, process steps, storage, distribution, intended use & dosage form.
• Example FMEA tables provided (Premises, Equipment, Materials, Utilities, Personnel, Production, Repackaging, Storage, Distribution).
• Highlights nitrosamine-specific assessment: sources of nitrite (water, air, inks) + vulnerable amines.

Appendix 2 – High-Risk Excipients & Contaminants

High-Risk Excipients (initial list, will expand)

• Ethanol (ethyl alcohol)
• 2-Propanol (isopropyl alcohol)
• Glycerol
• Hydrogenated starch hydrolysates (HSHs)
• Maltitol solution
• Propylene glycol
• Sorbitol solution
• Plus other polyols & surfactants possibly contaminated with DEG/EG (e.g., polyethylene glycol, polysorbates).

Key Contaminants & Controls

• Diethylene glycol (DEG) & Ethylene glycol (EG)
  • Industrial solvents; $\text{Limit}\le 0.10\;\%\;\text{v/v}$ in excipients.
  • Toxic: nephrotoxic, neurotoxic ⇒ fatal in children.
  • Controls: 100 % container sampling, GC/FID or HPLC/RID limit test, supplier qualification.
• Nitrosamines
  • Formed via nitrite + secondary amine reactions.
  • Carcinogenic; risk assessment & control strategy required (per WHO Annex 2, 2025).

Numerical / Statistical References

• Retest/expiry dates derived from stability: Stress + long-term data.
• DEG/EG safety limit example $\le 0.10\%\,(v/v)$.
• RPN calculation $RPN=S\times O\times D$ used for FMEA.

Cross-References to Other WHO / International Guidance

• WHO QRM (TRS 981, Annex 2).
• WHO Data Integrity (TRS 1033, Annex 4).
• WHO Validation of Computerized Systems (TRS 1019, App 5).
• EMA & PIC/S HBEL guidelines for shared facilities.
• ISO 31000 – generic risk-management framework.
• ICH Q9 (R1) – foundational QRM.

Ethical, Philosophical & Practical Implications

• Patient safety is paramount; even “inactive” ingredients can be lethal if contaminated.
• Manufacturers must adopt proactive rather than reactive quality culture.
• Transparency & traceability fight economically motivated adulteration.
• Continuous improvement aligns with ethical duty to minimise harm and environmental footprint.

Real-World Illustrations & Analogies

• 1937 sulfanilamide-DEG tragedy parallels modern cases (Haiti, Gambia, Uzbekistan) ⇒ reminder of repeating history when controls lapse.
• Supply chain likened to a relay race: every hand-off (manufacturer → trader → repacker → FPP maker) is a contamination risk node; QRM ensures each runner keeps the baton clean.

Formulae & Equations (LaTeX notation)

• Risk Priority Number $RPN = Severity\,(S) \times Occurrence\,(O) \times Detection\,(D)$
• DEG/EG maximum limit example $\text{[DEG\ or\ EG]} \le 0.10\,\%_{v/v}$ per container sample.

Study Tips

• Map each GMP clause to a real process in your facility to internalise requirements.
• Practise building a mini-FMEA table for an excipient you know.
• Re-draw supply chain diagrams, marking control points.
• Memorise the seven compulsory SOP clusters (equipment, OOS, maintenance, cleaning, personnel, complaints, recalls/returns).

End-of-Lecture Checklist

☐ Understand why excipient GMP matters for patient safety.
☐ Recall structure: 18 chapters + 2 appendices.
☐ Explain how QMS, QRM & life-cycle thinking interlink.
☐ List high-risk excipients & contaminants and their control strategies.
☐ Use $RPN$ formula to prioritise hazards.
☐ State documentation, stability & distribution essentials.